Peritoneal dialysis (PD) was the first dialytic therapy used to achieve euvolemia in individuals with refractory congestive heart failure. PD remains a viable therapy for the short-term management of refractory congestive heart failure, and fluid removal rates comparable to those obtained with the continuous extracorporeal therapies can be achieved. However, with advances in extracorporeal therapies, the role of PD in these situations is limited to those individuals in whom vascular access cannot be obtained or if extracorporeal therapies are not available. On the other hand, PD is the ultrafiltration therapy of choice for the long-term ambulatory management of individuals with refractory congestive heart failure, either as a palliative therapy or as a bridge to definitive surgery or transplantation. A reduction in hospitalization rates and an improvement in functional capacity can be expected under such circumstances; however, survival is unlikely to be affected.

Ganter G: Über die Beseitigung giftiger Stoffe aus dem Blute durch Dialyse. Münch Med Wochenschr 1923;70:1478–1480.
United States Renal Data System. Bethesda, US Department of Public Health and Human Services, Public Health Service, National Institutes of Health, 2000.
Rippe B, Stelin G: Simulations of peritoneal solute transport during CAPD. Application of two-pore formalism. Kidney Int 1989;35:1234–1244.
Rippe B, Stelin G, Haraldsson B: Computer simulations of peritoneal fluid transport in CAPD. Kidney Int 1991;40:315–325.
Pannekeet MM, Mulder JB, Weening JJ, Struijk DG, Zweers MM, Krediet RT: Demonstration of aquaporin-CHIP in peritoneal tissue of uremic and CAPD patients. Perit Dial Int 1996;16(suppl 1):S54–S57.
Devuyst O, Nielsen S, Cosyns JP, Smith BL, Agre P, Squifflet JP, Pouthier D, Goffin E: Aquaporin-1 and endothelial nitric oxide synthase expression in capillary endothelia of human peritoneum. Am J Physiol 1998;275:H234–H242.
Yang B, Folkesson HG, Yang J, Matthay MA, Ma T, Verkman AS: Reduced osmotic water permeability of the peritoneal barrier in aquaporin-1 knockout mice. Am J Physiol 1999;276:C76–C81.
Henderson LW: Peritoneal ultrafiltration dialysis: Enhanced urea transfer using hypertonic peritoneal dialysis fluid. J Clin Invest 1966;45:950–955.
Nolph KD, Hano JE, Teschan PE: Peritoneal sodium transport during hypertonic peritoneal dialysis. Physiologic mechanisms and clinical implications. Ann Intern Med 1969;70:931–941.
Chen TW, Khanna R, Moore H, Twardowski ZJ, Nolph KD: Sieving and reflection coefficients for sodium salts and glucose during peritoneal dialysis in rats. J Am Soc Nephrol 1991;2:1092–1100.
Nolph KD, Mactier R, Khanna R, Twardowski ZJ, Moore H, McGary T: The kinetics of ultrafiltration during peritoneal dialysis: The role of lymphatics. Kidney Int 1987;32:219–226.
Twardowski ZJ, Khanna R, Nolph KD: Osmotic agents and ultrafiltration in peritoneal dialysis. Nephron 1986;42:93–101.
Imholz AL, Koomen GC, Struijk DG, Arisz L, Krediet RT: Effect of dialysate osmolarity on the transport of low-molecular weight solutes and proteins during CAPD. Kidney Int 1993;43:1339–1346.
Heimbürger O, Waniewski J, Werynski A, Lindholm B: A quantitative description of solute and fluid transport during peritoneal dialysis. Kidney Int 1992;41:1320–1332.
Twardowski ZJ, Nolph KD, Khanna R, et al: Peritoneal equilibration test. Perit Dial Bull 1987;7:138–147.
Schneierson SJ: Continuous peritoneal irrigation in the treatment of intractable edema of cardiac origin. Am J Med Sci 1949;218:76–79.
Leiter L: The role and control of renal dysfunction in congestive heart failure. NY State J Med 1948;48:1803–1806.
Maxwell MH, Rockney RE, Kleeman CR, Twiss MR: Peritoneal dialysis. 1. Technique and applications. JAMA 1959;170:917–924.
Burns RO: Peritoneal dialysis: Clinical experience. N Engl J Med 1962;267:1060–1064.
Barry KG, Schwartz FD: Peritoneal dialysis: Current status and future applications. Pediatr Clin North Am 1964;11:593.
Lund HG, Hughes RK: Peritoneal dialysis before cardiac surgery. Ann Thorac Surg 1967;4:470–473.
Mailloux LU, Swartz CD, Onesti G, Heider C, Ramirez O, Brest AN: Peritoneal dialysis for refractory congestive heart failure. JAMA 1967;199:873–878.
Cairns KB, Porter GA, Kloster FE, Bristow JD, Griswold HE: Clinical and hemodynamic results of peritoneal dialysis for severe cardiac failure. Am Heart J 1968;76:227–234.
Rae AI, Hopper J Jr: Removal of refractory oedema fluid by peritoneal dialysis. Br J Urol 1968;40:336–343.
Chopra MP, Gulati RB, Portal RW, Aber CP: Peritoneal dialysis for pulmonary oedema after acute myocardial infarction. Br Med J 1970;3:77–80.
Raja RM, Krasnoff SO, Moros JG, Kramer MS, Rosenbaum JL: Repeated peritoneal dialysis in treatment of heart failure. JAMA 1970;213:2268–2269.
Malach M: Peritoneal dialysis for intractable heart failure in acute myocardial infarction. Am J Cardiol 1972;29:61–63.
Shilo S, Slotki IN, Iaina A: Improved renal function following acute peritoneal dialysis in patients with intractable congestive heart failure. Isr J Med Sci 1987;23:821–824.
Robson M, Bira A, Knobel B, et al: Peritoneal dialysis in refractory congestive heart failure. 2. Continuous ambulatory peritoneal dialysis. Perit Dial Bull 1983;3:133–134.
Weinrauch LA, Kaldany A, Miller DG, Yoburn DC, Belok S, Healy RW, Leland OS, D’Elia JA: Cardiorenal failure: Treatment of refractory biventricular failure by peritoneal dialysis. Uremia Invest 1984;8:1–8.
Kim D, Khanna R, Wu G, et al: Successful use of peritoneal dialysis in refractory heart failure. Perit Dial Bull 1985;5:127–130.
McKinnie JJ, Bourgeois RJ, Husserl FE: Long-term therapy for heart failure with continuous ambulatory peritoneal dialysis. Arch Intern Med 1985;145:1128–1129.
Rubin J, Ball R: Continuous ambulatory peritoneal dialysis as treatment of severe congestive heart failure in the face of chronic renal failure. Report of eight cases. Arch Intern Med 1986;146:1533–1535.
Mousson C, Tanter Y, Chalopin JM, Rebibou JM, Dentan G, Morelon P, Rifle G: Treatment of refractory congestive cardiac insufficiency by continuous peritoneal dialysis. Long-term course (in French). Presse Méd 1988;17:1617–1620.
König PS, Lhotta K, Kronenberg F, Joannidis M, Herold M: CAPD: A successful treatment in patients suffering from therapy-resistant congestive heart failure. Adv Perit Dial 1991;7:97–101.
McLigeyo SO: Intermittent peritoneal dialysis in the management of refractory heart failure. Cent Afr J Med 1992;38:421–424.
Stegmayr BG, Banga R, Lundberg L, Wikdahl AM, Plum-Wirell M: PD treatment for severe congestive heart failure. Perit Dial Int 1996;16(suppl 1):S231–S235.
Tormey V, Conlon PJ, Farrell J, Horgan J, Walshe JJ: Long-term successful management of refractory congestive cardiac failure by intermittent ambulatory peritoneal ultrafiltration. QJM 1996;89:681–683.
Ryckelynck JP, Lobbedez T, Valette B, Le Goff C, Mazouz O, Levaltier B, Potier JC, Hurault de Ligny B: Peritoneal ultrafiltration and treatment-resistant heart failure. Nephrol Dial Transplant 1998;13(suppl 4):56–59.
Elhalel-Dranitzki M, Rubinger D, Moscovici A, Haviv YS, Friedlaender MM, Silver J, Popovtzer MM: CAPD to improve quality of life in patients with refractory heart failure. Nephrol Dial Transplant 1998;13:3041–3042.
Freida P, Ryckelynck JP, Potier J, et al: Place de l’ultrafiltration péritonéale dans le traitement médical de l’insuffisance cardiaque au stade IV de la NYHA. Bull Dial Périt 1995;5:7–18.
Gokal R: Newer peritoneal dialysis solutions. Adv Ren Replace Ther 2000;7:302–309.
Ho-dac-Pannekeet MM, Schouten N, Langendijk MJ, Hiralall JK, de Waart DR, Struijk DG, Krediet RT: Peritoneal transport characteristics with glucose polymer based dialysate. Kidney Int 1996;50:979–986.
Rippe B, Levin L: Computer simulations of ultrafiltration profiles for an icodextrin-based peritoneal fluid in CAPD. Kidney Int 2000;57:2546–2556.
Mactier RA, Khanna R, Twardowski Z, Moore H, Nolph KD: Contribution of lymphatic absorption to loss of ultrafiltration and solute clearances in continuous ambulatory peritoneal dialysis. J Clin Invest 1987;80:1311–1316.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.